nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccini - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
anatossina stafilococcica
glaxosmithkline vaccines s.r.l. - altri vaccini batterici - altri vaccini batterici
influpozzi zonale
glaxosmithkline vaccines s.r.l. - vaccini influenzali - vaccini influenzali
fluvirin
evans vaccines limited - vaccini influenzali - vaccini influenzali
vaxigrip tetra
sanofi pasteur europe - influenza, antigene purificato - influenza, antigene purificato
coxevac
ceva santé animale - vaccino coxiella burnetii inattivato, ceppo nove mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.
bcg vaccine ssi sostanza secca con solvens
pro farma ag - mycobacterium bovis (stamm: danese ceppo 1331) - sostanza secca con solvens - preparazione cryodesiccata: mycobacterium mucca (stamm: danese ceppo 1331) 2-8 x 10e6 cfu, natrii hydrogenoglutamas anhydricus, per il vetro. il rilascio di: magnesio sulfas heptahydricus, kalii hydrogenophosphas, acido citricum monohydricum, asparaginum monohydricum, ammonii portato citras, glycerolum (85 per cento), acqua q.s. per una soluzione invece di 1 ml. - prevenzione della tubercolosi disseminata prima 1. compleanno - vaccini
bcg vaccine ssi sostanza secca con solvens
pro farma ag - sostanza secca con solvens
measles vaccine (live) polvere e solvente
paxvax berna gmbh - polvere e solvente